Profil
Steve M.
Sabus served as the Chief Commercial Officer at Turning Point Therapeutics, Inc. in 2022.
Prior to that, he was the Senior Vice President & Head-Oncology at Astellas Pharma US, Inc. He also held the position of General Manager at Astellas Pharma Canada, Inc. In 2022, he became the Chief Commercial Officer at Syndax Pharmaceuticals, Inc., where he served until 2024.
Mr. Sabus completed his undergraduate degree at the University of Northern Iowa.
Anciens postes connus de Steve M. Sabus
| Sociétés | Poste | Fin |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 15/03/2024 |
| TURG POIN | Corporate Officer/Principal | 01/08/2022 |
Astellas Pharma Canada, Inc.
 Astellas Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Canada, Inc. is a pharmaceutical company. It offers immunology, anti infective, cardiology, oncology and research and development products. The company is headquartered in Markham, Canada. | Corporate Officer/Principal | - |
Astellas Pharma US, Inc.
 Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Corporate Officer/Principal | - |
Formation de Steve M. Sabus
| University of Northern Iowa | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Astellas Pharma US, Inc.
Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Health Technology |
Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma Canada, Inc. is a pharmaceutical company. It offers immunology, anti infective, cardiology, oncology and research and development products. The company is headquartered in Markham, Canada. | Health Technology |
